Lead Product(s) : Ropidoxuridine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : WestPark Capital
Deal Size : $5.7 million
Deal Type : Public Offering
Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering
Details : The net proceeds from the offering will be used to advance the clinical development of IPdR (ropidoxuridine). It is being indicated for the treatment of IDH-wildtype Glioblastoma.
Product Name : IPdR
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 13, 2025
Lead Product(s) : Ropidoxuridine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : WestPark Capital
Deal Size : $5.7 million
Deal Type : Public Offering
Lead Product(s) : Ropidoxuridine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : WestPark Capital
Deal Size : $5.75 million
Deal Type : Public Offering
Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering
Details : The net proceeds from the offering will be used to advance the clinical development of IPdR (ropidoxuridine). It is being indicated for the treatment of IDH-wildtype Glioblastoma.
Product Name : IPdR
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 12, 2025
Lead Product(s) : Ropidoxuridine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : WestPark Capital
Deal Size : $5.75 million
Deal Type : Public Offering
Lead Product(s) : Ropidoxuridine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Shuttle Pharma Reaches Enrollment Milestone for Ropidoxuridine in Glioblastoma
Details : IPdR (ropidoxuridine) is a radiation sensitizing agent given during radiotherapy. It iscurrently being investigated for the treatment of IDH-wildtype glioblastoma.
Product Name : IPdR Prodrug
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 21, 2025
Lead Product(s) : Ropidoxuridine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ropidoxuridine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Shuttle Pharma Expands Ropidoxuridine Trial for Glioblastoma at UVA Cancer Center
Details : IPdR (ropidoxuridine) is a radiation sensitizing agent given during radiotherapy. It iscurrently being investigated for the treatment of IDH-wildtype glioblastoma.
Product Name : IPdR Prodrug
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 26, 2024
Lead Product(s) : Ropidoxuridine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ropidoxuridine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Alliance Global Partners
Deal Size : $4.5 million
Deal Type : Public Offering
Shuttle Pharmaceuticals Prices $4.5M Offering Under Nasdaq Rules
Details : The net proceeds will be used to fund the development of IPdR Prodrug (ropidoxuridine), which is being evaluated in the mid-stage clinical trial studies for the treatment of IDH-wildtype glioblastoma.
Product Name : IPdR Prodrug
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 29, 2024
Lead Product(s) : Ropidoxuridine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Alliance Global Partners
Deal Size : $4.5 million
Deal Type : Public Offering
Lead Product(s) : Ropidoxuridine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Shuttle Pharma Doses First Patients in Glioblastoma Treatment Phase 2 Trial
Details : IPdR (ropidoxuridine) is a radiation sensitizing agent given during radiotherapy. It iscurrently being investigated for the treatment of IDH-wildtype glioblastoma.
Product Name : IPdR Prodrug
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 29, 2024
Lead Product(s) : Ropidoxuridine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ropidoxuridine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Shuttle Completes Enrollment for Phase 2 Study of Ropidoxuridine
Details : IPdR (ropidoxuridine) is a radiation sensitizing agent given during radiotherapy. It is currently being investigated for the treatment of IDH-wildtype glioblastoma.
Product Name : IPdR Prodrug
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 28, 2024
Lead Product(s) : Ropidoxuridine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ropidoxuridine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Shuttle Pharma Expands Clinical Trial Sites for Ropidoxuridine in Glioblastoma
Details : IPdR (ropidoxuridine) is a radiation sensitizing agent given during radiotherapy. It is currently being investigated for the treatment of IDH-wildtype glioblastoma.
Product Name : IPdR Prodrug
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 16, 2024
Lead Product(s) : Ropidoxuridine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ropidoxuridine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Shuttle Pharma to Enroll Patients in Phase 2 Trial of Ropidoxuridine for Glioblastoma
Details : IPdR (ropidoxuridine) is a radiation sensitizing agent given during radiotherapy. It is currently being investigated for the treatment of IDH-wildtype glioblastoma.
Product Name : IPdR Prodrug
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 14, 2024
Lead Product(s) : Ropidoxuridine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ropidoxuridine
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Shuttle Gets FDA Approval for Phase II Trial of Ropidoxuridine in Glioblastoma
Details : IPdR (ropidoxuridine) is a radiation sensitizing agent given during radiotherapy. It iscurrently being investigated for the treatment of IDH-wildtype glioblastoma.
Product Name : IPdR Prodrug
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 01, 2024
Lead Product(s) : Ropidoxuridine
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable